OCGN News and Press, Ocugen, Inc. From 05/29/24

2024-05-29 12:53:53 ET Ocugen (NASDAQ: OCGN) stock price is doing well this year as investors focus on its ongoing drug trials and its milestones. It has soared by over 177% this year, outperforming the S&P 500, Nasdaq 100, and the iShars Biotechnology ETF (IBB), which has dropped b...

MALVERN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company will present at the 2024 BIO Internation...

2024-05-28 07:11:41 ET More on Ocugen Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value Ocugen: A Speculative Buy In Biotech Growing Clinical Trials To Billion-Dollar Revenues Read the full article on Seeking Alpha For further details see: Ocu...

MALVERN, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced its expected upcoming inclusion in the Russell 3000 &#x...

2024-05-24 08:10:00 ET Small biotech companies can be explosive. Massive gains above 100% in relatively short periods aren't that rare. That's what happened to Ocugen (NASDAQ: OCGN) this year. The company's shares are up 229% since January (as of this writing). As per usual, Ocugen ...

MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Arun Upadhyay, PhD, Chief Scientific Officer, Head o...

MALVERN, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete i...

2024-05-14 13:39:08 ET Ocugen, Inc. (OCGN) Q1 2024 Earnings Conference Call May 14, 2024, 8:30 am ET Company Participants Tiffany Hamilton - Head, Corporate Communications Shankar Musunuri - Chairman, CEO & Co-Founder Michael Breininger - Corporate Controller...

2024-05-14 08:02:08 ET More on Ocugen Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value Ocugen: A Speculative Buy In Biotech Growing Clinical Trials To Billion-Dollar Revenues Ocugen Q1 2024 Earnings Preview Ocugen stock jumps after $175M securiti...

All three first-in-class modifier gene therapy product candidates currently in the clinic with OCU400 Phase 3 in progress OCU400 on track to meet 2026 Biologics License Application (BLA) and Market Authorization Application (MAA) approval targets MALVERN, Pa., May 14, 2024 (GLOBE ...